In a presentation during the American Conference Institute’s Summit on Biosimilars, held June 25-27 in New York, New York, Laura Sim, JD, senior counsel at Amgen, and Vishal Gupta, JD, partner at Steptoe & Johnson LLP, discussed various naming and labeling considerations that stakeholders need to consider for biosimilars.
The naming and labeling of biosimilar and biologic products has previously caused controversy throughout the industry. The FDA officially released a finalized naming and labeling guideline in January 2017, and started to implement the new approach in November 2017.
The guideline constitutes the non-proprietary name of approved biosimilars and biologics to include a 4-letter suffix, devoid of meaning. In addition, the policy requires previously approved reference products to include the suffix as well; however, to date, no biologic approved prior to the release of the finalized guidance has been retroactively amended.
In a presentation during the American Conference Institute’s Summit on Biosimilars, held June 25-27 in New York, New York, Laura Sim, JD, senior counsel at Amgen, and Vishal Gupta, JD, partner at Steptoe & Johnson LLP, discussed various naming and labeling considerations to take into account.
Sim began her presentation by noting Amgen’s positive opinion of the FDA’s naming regulations because it “promotes patient safety and success of the market and will also enhance pharmacovigilance and the traceability of a drug.”
An important area to watch going forward in the process will be the naming of any potential interchangeable products, as well as how the FDA will address the addition of suffixes to already marketed products. Amgen, she said, has recommended a few key action items to the FDA to ensure the smooth implementation of suffixes to postmarketed products, such as:
Gupta then led a discussion around labeling practices for biosimilar medicines. There has been some litigation around what a biosimilar medicine should or should not legally include within its label. The FDA put out a draft guidance document in March 2016 specifying that a biosimilar drug label must contain:
Notably, the label guidance does not include the requirement of an interchangeability statement, biosimilarity study data, or statements about any extrapolation of data. “Going forward, I expect that the final guidance will be pretty consistent with the draft guidance the FDA has issued,” said Gupta.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.